Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants
Fig 2
Evaluation of the level of anti-APN1 IgG antibody among vaccinated mouse groups at different time points by an ELISA.
Mouse groups were immunized subcutaneously with recombinant APN1 alone or formulated with different adjuvants (CpG, MPL, QS21, and CMQ [CpG/MPL/QS21]). Control groups received 1×PBS alone or with adjuvants. Anti-APN1 IgG antibody levels were compared at different time points on days 10 (n = 9), 24 (n = 9), 38 (n = 9), and 180 (n = 4) after the first immunization in each mouse group. There was a significant difference in total IgG antibody levels between different immunization time points (days 10, 24, and 38) in each vaccine group (Adjusted P <0.05, paired-sample t-test). Comparing the anti-APN1 IgG antibodies in vaccinated mouse groups on day 38 revealed a significant difference (P < 0.0001, one-way ANOVA test), and the highest level of anti-APN1 IgG antibodies was observed in mice receiving APN1/CMQ.